Gregorio Basile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gregorio Basile has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Bartoloni
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
4 shared publications - Alberto Antonelli
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
1 shared publication - Alberto Enrico Maraolo
Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, 80131 Naples, Italy
1 shared publication Alberto Farese
Unit of Infectious and Tropical Diseases, Careggi University Hospital, Florence, Italy
1 shared publicationAlberto Moggi Pignone
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
1 shared publication- Alessandra Mularoni
Unit of Infectious Diseases IRCCS‐ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione Palermo Italy
1 shared publication
Latest Publications
- Open Access
- 2 July 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (7) , 1371-1378
Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications
Purpose: SARS-CoV-2 infection in immunocompromised hosts is challenging, and prolonged viral shedding can be a common complication in these patients. We describe the clinical, immunological, and virological course of a patient with eosinophilic granulomatosis with polyangiitis, who developed the status of long-term asymptomatic SARS-CoV-2 carrier for more than 7 months. Methods: Over the study period, the patient underwent 20 RT-PCR tests for SARS-CoV-2 detection on nasopharyngeal swabs. In addition, viral cultures and genetic investigation of SARS-CoV-2 were performed. As for immunological assessment, serological and specific T-cell testing was provided at different time points. Results: Despite the patient showing a deep drug-induced B and T adaptive immunity impairment, he did not experience COVID-19 progression to severe complications, and the infection remained asymptomatic during the follow-up period, but he was not able to achieve viral clearance for more than 7 months. The infection was finally cleared by SARS-CoV-2-specific monoclonal antibody treatment, after that remdesivir and convalescent plasma failed in this scope. The genetic investigations evidenced that the infection was sustained by multiple viral subpopulations that had apparently evolved intra-host during the infection. Conclusion: Our case suggests that people with highly impaired B- and T-cell adaptive immunity can prevent COVID-19 progression to severe complications, but they may not be able to clear SARS-CoV-2 infection. Immunocompromised hosts with a long-term infection may play a role in the emergence of viral variants.
- 2 July 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (7) , 1371-1378
Open AccessLong-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications
Purpose: SARS-CoV-2 infection in immunocompromised hosts is challenging, and prolonged viral shedding can be a common complication in these patients. We describe the clinical, immunological, and virological course of a patient with eosinophilic granulomatosis with polyangiitis, who developed the status of long-term asymptomatic SARS-CoV-2 carrier for more than 7 months. Methods: Over the study period, the patient underwent 20 RT-PCR tests for SARS-CoV-2 detection on nasopharyngeal swabs. In addition, viral cultures and genetic investigation of SARS-CoV-2 were performed. As for immunological assessment, serological and specific T-cell testing was provided at different time points. Results: Despite the patient showing a deep drug-induced B and T adaptive immunity impairment, he did not experience COVID-19 progression to severe complications, and the infection remained asymptomatic during the follow-up period, but he was not able to achieve viral clearance for more than 7 months. The infection was finally cleared by SARS-CoV-2-specific monoclonal antibody treatment, after that remdesivir and convalescent plasma failed in this scope. The genetic investigations evidenced that the infection was sustained by multiple viral subpopulations that had apparently evolved intra-host during the infection. Conclusion: Our case suggests that people with highly impaired B- and T-cell adaptive immunity can prevent COVID-19 progression to severe complications, but they may not be able to clear SARS-CoV-2 infection. Immunocompromised hosts with a long-term infection may play a role in the emergence of viral variants.
- Open Access
- 1 July 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 108, 231-236
Use of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy
- 1 July 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 108, 231-236
Open AccessUse of the FebriDx point-of-care test for the exclusion of SARS-CoV-2 diagnosis in a population with acute respiratory infection during the second (COVID-19) wave in Italy
- Open Access
- 8 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (5) , 1127
Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections
Background: Limited and wide-ranging data are available on the recurrent Clostridioides difficile infection (rCDI) incidence rate. Methods: We performed a cohort study with the aim to assess the incidence of and risk factors for rCDI. Adult patients with a first CDI, hospitalized in 15 Italian hospitals, were prospectively included and followed-up for 30 d after the end of antimicrobial treatment for their first CDI. A case–control study was performed to identify risk factors associated with 30-day onset rCDI. Results: Three hundred nine patients with a first CDI were included in the study; 32% of the CDI episodes (99/309) were severe/complicated; complete follow-up was available for 288 patients (19 died during the first CDI episode, and 2 were lost during follow-up). At the end of the study, the crude all-cause mortality rate was 10.7% (33 deaths/309 patients). Two hundred seventy-one patients completed the follow-up; rCDI occurred in 21% of patients (56/271) with an incidence rate of 72/10,000 patient-days. Logistic regression analysis identified exposure to cephalosporin as an independent risk factor associated with rCDI (RR: 1.7; 95% CI: 1.1–2.7, p = 0.03). Conclusion: Our study confirms the relevance of rCDI in terms of morbidity and mortality and provides a reliable estimation of its incidence.
- 8 March 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (5) , 1127
Open AccessProspective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections
Background: Limited and wide-ranging data are available on the recurrent Clostridioides difficile infection (rCDI) incidence rate. Methods: We performed a cohort study with the aim to assess the incidence of and risk factors for rCDI. Adult patients with a first CDI, hospitalized in 15 Italian hospitals, were prospectively included and followed-up for 30 d after the end of antimicrobial treatment for their first CDI. A case–control study was performed to identify risk factors associated with 30-day onset rCDI. Results: Three hundred nine patients with a first CDI were included in the study; 32% of the CDI episodes (99/309) were severe/complicated; complete follow-up was available for 288 patients (19 died during the first CDI episode, and 2 were lost during follow-up). At the end of the study, the crude all-cause mortality rate was 10.7% (33 deaths/309 patients). Two hundred seventy-one patients completed the follow-up; rCDI occurred in 21% of patients (56/271) with an incidence rate of 72/10,000 patient-days. Logistic regression analysis identified exposure to cephalosporin as an independent risk factor associated with rCDI (RR: 1.7; 95% CI: 1.1–2.7, p = 0.03). Conclusion: Our study confirms the relevance of rCDI in terms of morbidity and mortality and provides a reliable estimation of its incidence.
- 1 September 2020
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 45 (3) , 264-265
Tolvaptan efficacy and drug-drug interactions
Article: Tolvaptan efficacy and drug-drug interactions - Minerva Endocrinologica 2020 September;45(3):264-5 - Minerva Medica - Journals
- 1 September 2020
- Published by Edizioni Minerva Medica in Minerva Endocrinology
- Vol. 45 (3) , 264-265
Tolvaptan efficacy and drug-drug interactions
Article: Tolvaptan efficacy and drug-drug interactions - Minerva Endocrinologica 2020 September;45(3):264-5 - Minerva Medica - Journals